Novartis AG (NVS)

90.10
1.50 1.70
NYSE : Health Technology
Prev Close 88.58
Open 88.85
Day Low/High 88.81 / 89.56
52 Wk Low/High 74.97 / 96.31
Volume 1.11M
Avg Volume 2.05M
Exchange NYSE
Shares Outstanding 2.55B
Market Cap 223.92B
EPS 5.50
P/E Ratio 16.46
Div & Yield 1.84 (2.07%)

Latest News

Tilray Stock Gains Ahead of Highly Anticipated Earnings Release

Tilray Stock Gains Ahead of Highly Anticipated Earnings Release

Tilray will look to sustain a sanguine sentiment on cannabis stocks on Tuesday.

Fear Not the Curve, Sizing Up Earnings and Ways to Play Amgen: Market Recon

Fear Not the Curve, Sizing Up Earnings and Ways to Play Amgen: Market Recon

Understanding yourself and the investing environment you are in are keys to avoiding panic brought on by fear.

Should You Go for the 'Easy Money' in Novartis?

Should You Go for the 'Easy Money' in Novartis?

NVS been in an uptrend the past twelve months.

Jim Cramer: Looking for Netflix Action? Don't Be a Hero

Jim Cramer: Looking for Netflix Action? Don't Be a Hero

Stranger things have happened, but with NFLX's subscriber miss, the stock just became hard money, joining the likes of Johnson & Johnson and CSX Corp.

Market Yin and Yang

We've got some push-pull in pre-market trading as moves lower in Netflix , Limelight Networks , United Rentals , SAP and Alcoa duel with Apple , which is moving higher pre-market, and positive moves in Novartis , eBay , Phillip Morris International ...

China's Drugmakers Under Scrutiny After Stanford Admissions Scandal

China's Drugmakers Under Scrutiny After Stanford Admissions Scandal

Chinese authorities are auditing the books of 77 drugmakers, including three multinationals, they say were selected at random. Were they motivated by embarrassment over a college-admissions payment made by a Chinese pharmaceuticals' tycoon?

Novartis Is a Difficult Stock to Trade or Own - Suggested Risk Point

Novartis Is a Difficult Stock to Trade or Own - Suggested Risk Point

Let's review the charts and indicators this morning.

Jim Cramer: The Forbidden City of Stock Sectors

Jim Cramer: The Forbidden City of Stock Sectors

Now, we know that if we got any sort of truce in the trade war, with the exception of the financials, these hated sectors would be loved.

Fibocall: Thursday Technical Texts

Kass: Tilray Is Promising but I Prefer This Other Stock in the Pot Space

Kass: Tilray Is Promising but I Prefer This Other Stock in the Pot Space

Tilray will not be cash flow positive for another 2-3 years - that's not quick enough progress for me given its $7 billion dollar capitalization.

Stock of the Day - Tilray

Pot stocks like Tilray have very ambitious valuations but the potential upside (in mergers and, fundamentally in food, drink, supplemental and medical applications) are undeniably immense. The view of a possible rapid rise in revenues and profits (a...

Tilray Stock Lights Up as Partnerships Obscure Profitability Problem

Tilray Stock Lights Up as Partnerships Obscure Profitability Problem

The move was helped by the TLRY's deals with AB InBev for beverages and Novartis for medical applications.

Jim Cramer: How to Win Now, With or Without China

Jim Cramer: How to Win Now, With or Without China

If we can advance without China then who the heck knows where we can go with it.

Gilead Shares Fall After Hours as Company Misses on Quarterly Earnings

Gilead Shares Fall After Hours as Company Misses on Quarterly Earnings

Medicine is a slow business and I view Gilead Sciences as a hold for now.

Excuse Me, Would You Like Some Cannabis With Your Coffee?

Excuse Me, Would You Like Some Cannabis With Your Coffee?

CBD could make coffee an around the clock craze.

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

One of pharma's biggest CEO's talks M&A action on the exchange.

Chart of the Day, Part 2: A Closer Look at Constellation's Big Cannabis Bet

Chart of the Day, Part 2: A Closer Look at Constellation's Big Cannabis Bet

Canopy Growth's smoking engine won't necessarily ensure smooth sailing for Constellation.

Novartis Stock Is Poised to Rise Another 15% From Here

Novartis Stock Is Poised to Rise Another 15% From Here

The stock's performance has been impressive in the past three months.

Jim Cramer: Innovation Is on Display at the J.P. Morgan Healthcare Conference

Jim Cramer: Innovation Is on Display at the J.P. Morgan Healthcare Conference

We're out in San Francisco this week covering the amazing innovations that so many companies reveal at this annual conference.

Tilray Is Now a Top-Tier Cannabis Play

Tilray Is Now a Top-Tier Cannabis Play

I'd be most interested in buying this name after a cap raise which I expect in the first quarter of 2019.

Tilray Stock Burns Higher With Anheuser-Busch Beverage Deal

Tilray Stock Burns Higher With Anheuser-Busch Beverage Deal

Pot stock partnerships are a gateway to gains for cannabis investors.

Tilray Stock Higher Ahead of First Post-Legalization Earnings Release

Tilray Stock Higher Ahead of First Post-Legalization Earnings Release

Tilray will have a lot to tackle this evening.

A Reckless Fed: Market Recon

A Reckless Fed: Market Recon

It's time for the central bank to show the same level of concern for their misplaced aggression.

Tesla Jumps After Judge Makes SEC Settlement Official: LIVE MARKETS BLOG

Tesla Jumps After Judge Makes SEC Settlement Official: LIVE MARKETS BLOG

Tesla will pay $20 million as part of the settlement with Elon Musk paying another $20 million.

Novartis Is Ready to Rally From a Large Base Pattern

Novartis Is Ready to Rally From a Large Base Pattern

Let's check out the latest charts and indicators for some technical guidance.

Jim Cramer: Reefer Madness

Jim Cramer: Reefer Madness

Tilray's a disruptive company for many industries.

Gilead's Earnings Fail to Impress

Gilead's Earnings Fail to Impress

The company is losing sales aggressively as it fails to create any business substantial enough to make up for the shrinking sales in its Hepatitis C drugs.